These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30560761)

  • 21. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM; Montgomery SM; Adlard NE; Kroes MA
    J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
    Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
    J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.
    Sangroongruangsri S; Kittrongsiri K; Charatcharoenwitthaya P; Sobhonslidsuk A; Chaikledkaew U
    Clinicoecon Outcomes Res; 2021; 13():703-715. PubMed ID: 34349534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 28. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
    Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
    Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.
    Hashemi-Meshkini A; Zekri HS; Karimi-Yazdi H; Zaboli P; Sahraian MA; Nikfar S
    Iran J Neurol; 2018 Jul; 17(3):123-128. PubMed ID: 30886679
    [No Abstract]   [Full Text] [Related]  

  • 31. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand.
    Sangroongruangsri S; Chaikledkaew U; Hanusaha P; Ratanapakorn T; Ruamviboonsuk P
    Clinicoecon Outcomes Res; 2021; 13():917-926. PubMed ID: 34795492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
    Aungsumart S; Apiwattanakul M
    PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
    Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
    Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.